Summary & Overview
HCPCS Level II J1071: Injection, Testosterone Cypionate, 1 mg
HCPCS Level II code J1071 identifies a 1 mg injection of testosterone cypionate, an androgen replacement therapy commonly used in male hypogonadism and certain gender-affirming care. As a drug-specific HCPCS Level II code, J1071 is used on medical claims to report administered units of this injectable medication and matters for billing, coverage determinations, and drug utilization monitoring across payers nationally. Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for testosterone cypionate injections, common sites of service where administration occurs, and the billing implications of using an HCPCS Level II drug code. The publication outlines typical coverage considerations, payer variation in drug benefit management, and common billing challenges such as unit reporting and site-specific payment policies. It also summarizes available benchmarks and notable policy updates that affect injectable testosterone products at a national level. This resource is intended for billing professionals, clinicians who order or administer injectable therapies, and policy analysts seeking a practical reference on use and reporting of HCPCS Level II code J1071.
Billing Code Overview
HCPCS Level II code J1071 represents an injection of testosterone cypionate, 1 mg. This code denotes a single-unit medication administration for testosterone cypionate formulated for intramuscular injection.
Service Type: Injectable medication administration
Typical Site of Service: Clinic or office-based outpatient setting, ambulatory infusion center, or other outpatient administration sites
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A male patient in his 30s–60s with diagnosed primary hypogonadism or testosterone deficiency presents to an outpatient clinic for intramuscular testosterone replacement therapy. The clinician orders J1071 (injection, testosterone cypionate, 1 mg) to be administered in a clinic or infusion suite. The typical workflow includes: pre-injection assessment (vital signs, review of recent testosterone level and baseline labs), informed consent and screening for contraindications (prostate cancer screening and hematocrit check), medication preparation and verification, administration by a licensed nurse via deep intramuscular injection (usually gluteal or deltoid), post-injection observation for immediate adverse reactions, documentation of lot number and dose, and scheduling of follow-up dosing and laboratory monitoring (serum testosterone, hematocrit, PSA as appropriate). Typical sites of service are outpatient clinic, physician office, or ambulatory infusion center. Common clinical scenarios include initiation of hormone replacement for documented low serum testosterone or maintenance dosing for established therapy, with dosage and interval determined by the ordering clinician.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Report when part of a multi-dose vial is discarded and the payer requires reporting of wasted drug |